Pathogen inactivation of human serum facilitates its clinical use for islet cell culture and subsequent transplantation.

Serum is regarded as an essential supplement to promote survival and growth of cells during culture. However, the potential risk of transmitting diseases disqualifies the use of serum for clinical cell therapy in most countries. Hence, most clinical cell therapy programs have replaced human serum wi...

Cijeli opis

Bibliografski detalji
Glavni autori: Ståhle, M, Brandhorst, D, Korsgren, O, Knutson, F
Format: Journal article
Jezik:English
Izdano: 2011
_version_ 1826292278363160576
author Ståhle, M
Brandhorst, D
Korsgren, O
Knutson, F
author_facet Ståhle, M
Brandhorst, D
Korsgren, O
Knutson, F
author_sort Ståhle, M
collection OXFORD
description Serum is regarded as an essential supplement to promote survival and growth of cells during culture. However, the potential risk of transmitting diseases disqualifies the use of serum for clinical cell therapy in most countries. Hence, most clinical cell therapy programs have replaced human serum with human serum albumin, which can result in inferior quality of released cell products. Photochemical treatment of different blood products utilizing Intercept® technology has been shown to inactivate a broad variety of pathogens of RNA and DNA origin. The present study assesses the feasibility of using pathogen-inactivated, blood group-compatible serum for use in human pancreatic islet culture. Isolated human islets were cultured at 37°C for 3-4 days in CMRL 1066 supplemented with 10% of either pathogen-inactivated or nontreated human serum. Islet quality assessment included glucose-stimulated insulin release (perifusion), ADP/ATP ratio, cytokine expression, and posttransplant function in diabetic nude mice. No differences were found between islets cultured in pathogen-inactivated or control serum regarding stimulated insulin release, intracellular insulin content, and ADP/ATP ratio. Whether media was supplemented with treated or nontreated serum, islet expression of IL-6, IL-8, MCP-1, or tissue factor was not affected. The final diabetes-reversal rate of mice receiving islets cultured in pathogen-inactivated or nontreated serum was 78% and 87%, respectively (NS). As reported here, pathogen-inactivated human serum does not affect viability or functional integrity of cultured human islets. The implementation of this technology for RNA- and DNA-based pathogen inactivation should enable reintroduction of human serum for clinical cell therapy.
first_indexed 2024-03-07T03:12:13Z
format Journal article
id oxford-uuid:b495cc8a-37e8-4b3d-b8be-7e621e2a96cf
institution University of Oxford
language English
last_indexed 2024-03-07T03:12:13Z
publishDate 2011
record_format dspace
spelling oxford-uuid:b495cc8a-37e8-4b3d-b8be-7e621e2a96cf2022-03-27T04:27:12ZPathogen inactivation of human serum facilitates its clinical use for islet cell culture and subsequent transplantation.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:b495cc8a-37e8-4b3d-b8be-7e621e2a96cfEnglishSymplectic Elements at Oxford2011Ståhle, MBrandhorst, DKorsgren, OKnutson, FSerum is regarded as an essential supplement to promote survival and growth of cells during culture. However, the potential risk of transmitting diseases disqualifies the use of serum for clinical cell therapy in most countries. Hence, most clinical cell therapy programs have replaced human serum with human serum albumin, which can result in inferior quality of released cell products. Photochemical treatment of different blood products utilizing Intercept® technology has been shown to inactivate a broad variety of pathogens of RNA and DNA origin. The present study assesses the feasibility of using pathogen-inactivated, blood group-compatible serum for use in human pancreatic islet culture. Isolated human islets were cultured at 37°C for 3-4 days in CMRL 1066 supplemented with 10% of either pathogen-inactivated or nontreated human serum. Islet quality assessment included glucose-stimulated insulin release (perifusion), ADP/ATP ratio, cytokine expression, and posttransplant function in diabetic nude mice. No differences were found between islets cultured in pathogen-inactivated or control serum regarding stimulated insulin release, intracellular insulin content, and ADP/ATP ratio. Whether media was supplemented with treated or nontreated serum, islet expression of IL-6, IL-8, MCP-1, or tissue factor was not affected. The final diabetes-reversal rate of mice receiving islets cultured in pathogen-inactivated or nontreated serum was 78% and 87%, respectively (NS). As reported here, pathogen-inactivated human serum does not affect viability or functional integrity of cultured human islets. The implementation of this technology for RNA- and DNA-based pathogen inactivation should enable reintroduction of human serum for clinical cell therapy.
spellingShingle Ståhle, M
Brandhorst, D
Korsgren, O
Knutson, F
Pathogen inactivation of human serum facilitates its clinical use for islet cell culture and subsequent transplantation.
title Pathogen inactivation of human serum facilitates its clinical use for islet cell culture and subsequent transplantation.
title_full Pathogen inactivation of human serum facilitates its clinical use for islet cell culture and subsequent transplantation.
title_fullStr Pathogen inactivation of human serum facilitates its clinical use for islet cell culture and subsequent transplantation.
title_full_unstemmed Pathogen inactivation of human serum facilitates its clinical use for islet cell culture and subsequent transplantation.
title_short Pathogen inactivation of human serum facilitates its clinical use for islet cell culture and subsequent transplantation.
title_sort pathogen inactivation of human serum facilitates its clinical use for islet cell culture and subsequent transplantation
work_keys_str_mv AT stahlem pathogeninactivationofhumanserumfacilitatesitsclinicaluseforisletcellcultureandsubsequenttransplantation
AT brandhorstd pathogeninactivationofhumanserumfacilitatesitsclinicaluseforisletcellcultureandsubsequenttransplantation
AT korsgreno pathogeninactivationofhumanserumfacilitatesitsclinicaluseforisletcellcultureandsubsequenttransplantation
AT knutsonf pathogeninactivationofhumanserumfacilitatesitsclinicaluseforisletcellcultureandsubsequenttransplantation